Immatics (IMTX) Enterprise Value (2019 - 2026)
Immatics (IMTX) posted Enterprise Value of -$546.3 million for Q4 2025, down 8.47% sequentially from -$503.7 million in Q3 2025, and up 15.42% YoY from -$473.3 million in Q4 2024.
Analysis
Immatics (IMTX) Enterprise Value (2019 - 2026) Analysis & Trends
Immatics has reported Enterprise Value for 7 years, with the latest figure at -$546.3 million in Q4 2025.
- Quarterly Enterprise Value rose 15.42% year-over-year to -$546.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$546.3 million (up 15.42% YoY) and the FY2025 annual result came in at -$530.3 million, up 18.95% from the prior year.
- Enterprise Value fell to -$546.3 million in Q4 2025 per IMTX's latest filing, from -$503.7 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$166.0 million in Q4 2021 and troughed at -$645.9 million in Q4 2024.
- A 5-year average of -$415.8 million and a median of -$398.4 million in 2023 frame the typical range for Enterprise Value.
- The widest YoY moves for Enterprise Value: up 39.98% in 2021, down 146.41% in 2021.
- Over 5 years, Enterprise Value stood at -$166.0 million in 2021, then sank by 122.6% to -$369.5 million in 2022, then retreated by 24.0% to -$458.2 million in 2023, then slumped by 40.96% to -$645.9 million in 2024, then increased by 15.42% to -$546.3 million in 2025.
- According to Business Quant data, Enterprise Value over the past three periods registered -$546.3 million, -$503.7 million, and -$541.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Immatics | 1.17 Bn | 711.21 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 900.93 Mn |
| Mar 31, 2026 | 788.25 Mn |
| Dec 31, 2025 | 861.42 Mn |
| Sep 30, 2025 | 531.94 Mn |
| Jun 30, 2025 | 112.65 Mn |
| Mar 31, 2025 | -23.78 Mn |
| Dec 31, 2024 | 218.31 Mn |
| Sep 30, 2024 | 637.76 Mn |
| Jun 30, 2024 | 625.75 Mn |
| Mar 31, 2024 | 425.11 Mn |
| Dec 31, 2023 | 433.21 Mn |
| Sep 30, 2023 | 489.40 Mn |
| Jun 30, 2023 | 506.24 Mn |
| Mar 31, 2023 | 175.03 Mn |
| Dec 31, 2022 | 298.26 Mn |
| Sep 30, 2022 | 317.37 Mn |
| Jun 30, 2022 | 201.96 Mn |
| Mar 31, 2022 | 219.12 Mn |
| Dec 31, 2021 | 679.73 Mn |
| Sep 30, 2021 | 419.75 Mn |